232 related articles for article (PubMed ID: 27226351)
1. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
Dickinson PA; Cantarini MV; Collier J; Frewer P; Martin S; Pickup K; Ballard P
Drug Metab Dispos; 2016 Aug; 44(8):1201-12. PubMed ID: 27226351
[TBL] [Abstract][Full Text] [Related]
2. A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma.
Venkatesh B; Yuile A; McKay MJ; Narayanan S; Wheeler H; Itchins M; Pavlakis N; Clarke SJ; Molloy MP
Ther Drug Monit; 2024 Jun; 46(3):332-343. PubMed ID: 38263583
[TBL] [Abstract][Full Text] [Related]
3. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Vishwanathan K; Dickinson PA; So K; Thomas K; Chen YM; De Castro Carpeño J; Dingemans AC; Kim HR; Kim JH; Krebs MG; Chih-Hsin Yang J; Bui K; Weilert D; Harvey RD
Br J Clin Pharmacol; 2018 Jun; 84(6):1156-1169. PubMed ID: 29381826
[TBL] [Abstract][Full Text] [Related]
4. Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.
Rood JJM; van Haren MJ; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2020 Jan; 177():112871. PubMed ID: 31539712
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.
Ishikawa E; Yokoyama Y; Chishima H; Kasai H; Kuniyoshi O; Kimura M; Hakamata J; Nakada H; Suehiro N; Nakaya N; Nakajima H; Ikemura S; Kawada I; Yasuda H; Terai H; Jibiki A; Kawazoe H; Soejima K; Muramatsu H; Suzuki S; Nakamura T
Invest New Drugs; 2023 Feb; 41(1):122-133. PubMed ID: 36637703
[TBL] [Abstract][Full Text] [Related]
6. Absolute Bioavailability of Osimertinib in Healthy Adults.
Vishwanathan K; So K; Thomas K; Bramley A; English S; Collier J
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):198-207. PubMed ID: 29683562
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and pharmacokinetic study of deuterated osimertinib.
Zhan X; Bao S; Li X; Zhou S; Dahar MR; Lin N; Chen X; Niu C; Ji K; Wu Y; Zeng K; Tang Z; Yu L
Biopharm Drug Dispos; 2023 Apr; 44(2):165-174. PubMed ID: 36649539
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein.
Meng J; Liu XY; Ma S; Zhang H; Yu SD; Zhang YF; Chen MX; Zhu XY; Liu Y; Yi L; Ding XL; Chen XY; Miao LY; Zhong DF
Acta Pharmacol Sin; 2019 Jul; 40(7):980-988. PubMed ID: 30382184
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study.
Zhao H; Cao J; Chang J; Zhang Z; Yang L; Wang J; Cantarini M; Zhang L
J Clin Pharmacol; 2018 Apr; 58(4):504-513. PubMed ID: 29239002
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
Ishikawa E; Yokoyama Y; Chishima H; Kuniyoshi O; Sato I; Nakaya N; Nakajima H; Kimura M; Hakamata J; Suehiro N; Nakada H; Ikemura S; Jibiki A; Kawazoe H; Muramatsu H; Suzuki S; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123245. PubMed ID: 35436724
[TBL] [Abstract][Full Text] [Related]
13. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.
McKillop D; Hutchison M; Partridge EA; Bushby N; Cooper CM; Clarkson-Jones JA; Herron W; Swaisland HC
Xenobiotica; 2004 Oct; 34(10):917-34. PubMed ID: 15764411
[TBL] [Abstract][Full Text] [Related]
14. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.
Rossi A; Muscarella LA; Di Micco C; Carbonelli C; D'alessandro V; Notarangelo S; Palomba G; Sanpaolo G; Taurchini M; Graziano P; Maiello E
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1281-1288. PubMed ID: 29095090
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
Zhou P; Chen G; Gao M; Wu J
Bioorg Med Chem; 2018 Dec; 26(23-24):6135-6145. PubMed ID: 30442506
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
[TBL] [Abstract][Full Text] [Related]
18. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
19. Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans.
Meng J; Zhang H; Bao JJ; Chen ZD; Liu XY; Zhang YF; Jiang Y; Miao LY; Zhong DF
Acta Pharmacol Sin; 2022 Feb; 43(2):494-503. PubMed ID: 33927359
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report.
Matsunashi A; Fujimoto D; Hosoya K; Irie K; Fukushima S; Tomii K
Invest New Drugs; 2020 Aug; 38(4):1192-1195. PubMed ID: 31486987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
